{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T18:31:35Z","timestamp":1725042695354},"reference-count":91,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Given the recent approvals of new agents for acute myeloid leukemia (AML), a clinical trial pipeline stocked with novel therapies, and the rapid integration of imaginative approaches in diseases like acute lymphocytic leukemia and chronic lymphocytic leukemia, it is reasonable to ask whether treatment of AML might finally depart from the classical cytotoxic induction therapy that has been employed since the 1970s. However, for better or worse, in 2018, cytotoxic induction regimens remain the standard of care for most patients. Indeed, the future likely lies in combinations of therapies that act with a spectrum of mechanisms. Using a case-based format, this review will outline current treatment expectations for patients according to karyotypic risk and familiarize readers with the basis for common induction choices. Relapsed\/refractory disease may be especially amenable to interventions with novel agents or clinical trials; however, there are still some patients who most benefit from intensive chemotherapy. This review will outline risk systems that help the practitioner identify those with the best chances for response and survival. Finally, clinical tools, including geriatric assessments and comorbidity calculators, may help clinicians recognize patients for whom disease risk and comorbidity tip the balance against classical chemotherapy, a frequent challenge for those who treat this devastating disease.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.51","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"51-62","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Cytotoxic therapy in acute myeloid leukemia: not quite dead yet"],"prefix":"10.1182","volume":"2018","author":[{"given":"Laura C.","family":"Michaelis","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2019111520473357900_B1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.beha.2017.09.010","article-title":"AML in 2017: Advances in clinical practice","volume":"30","author":"Rowe","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"2019111520473357900_B2","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"2019111520473357900_B3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2016.306","article-title":"Acute myeloid leukemia therapy and the chosen people","volume":"31","author":"Estey","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2019111520473357900_B4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/leu.2015.188","article-title":"Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2019111520473357900_B5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41375-018-0168-z","article-title":"New drugs in AML: uses and abuses","volume":"32","author":"Estey","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2019111520473357900_B6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2017.56","article-title":"How good are we at predicting the fate of someone with acute myeloid leukaemia?","volume":"31","author":"Estey","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2019111520473357900_B7","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable (\u2018minimal\u2019) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2019111520473357900_B8","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2015.76","article-title":"Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2019111520473357900_B9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2019111520473357900_B10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2019111520473357900_B11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2019111520473357900_B12","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111520473357900_B13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.5858\/arpa.2010-0482-RS","article-title":"Core-binding factor acute myeloid leukemia","volume":"135","author":"Sangle","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2019111520473357900_B14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/leu.2017.18","article-title":"Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group","volume":"31","author":"Jahn","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2019111520473357900_B15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111520473357900_B16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"2019111520473357900_B17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111520473357900_B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hem.V14.3.7298","article-title":"The case for abandoning induction chemotherapy","volume":"14","author":"Pollyea","year":"2017","journal-title":"The Hematologist"},{"issue":"7","key":"2019111520473357900_B19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","article-title":"Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial","volume":"32","author":"Paschka","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2019111520473357900_B20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"4","key":"2019111520473357900_B21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111520473357900_B22","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"32","key":"2019111520473357900_B23","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9825","key":"2019111520473357900_B24","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"2019111520473357900_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111520473357900_B26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"2019111520473357900_B27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111520473357900_B28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-07-657403","article-title":"Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups","volume":"127","author":"Luskin","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111520473357900_B29","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155]","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111520473357900_B30","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2011-06-361410","article-title":"A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia","volume":"118","author":"Lee","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111520473357900_B31","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111520473357900_B32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2016-04-712091","article-title":"Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia","volume":"128","author":"Burnett","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111520473357900_B33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","article-title":"Sense and nonsense of high-dose cytarabine for acute myeloid leukemia","volume":"121","author":"L\u00f6wenberg","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111520473357900_B34","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111520473357900_B35","article-title":"Phase 1\/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms [published online ahead of print 17 April 2018]","author":"Halpern","journal-title":"Leukemia"},{"key":"2019111520473357900_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.339.339","article-title":"Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age \u226560 years: analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial [abstract]","volume":"128","author":"Foran","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111520473357900_B37","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"L\u00f6wenberg","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111520473357900_B38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2019111520473357900_B39","first-page":"1903","article-title":"Midostaurin in FLT3-mutated acute myeloid leukemia","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111520473357900_B40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111520473357900_B41","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2019111520473357900_B42","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2015-01-561373","article-title":"Current challenges in clinical development of \u201ctargeted therapies\u201d: the case of acute myeloid leukemia","volume":"125","author":"Estey","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520473357900_B43","article-title":"An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations [abstract]","volume":"130","author":"Larson","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2019111520473357900_B44","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","article-title":"Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111520473357900_B45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019111520473357900_B46","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Serve","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111520473357900_B47","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1200\/JCO.2009.25.8616","article-title":"\u201cI am older, not elderly,\u201d said the patient with acute myeloid leukemia","volume":"28","author":"Schiffer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111520473357900_B48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/asheducation-2017.1.45","article-title":"How and when to decide between epigenetic therapy and chemotherapy in patients with AML","volume":"2017","author":"Dombret","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111520473357900_B49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2019111520473357900_B50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2014.216","article-title":"Management of older or unfit patients with acute myeloid leukemia","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111520473357900_B51","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111520473357900_B52","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111520473357900_B53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3324\/haematol.2015.132654","article-title":"Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT","volume":"101","author":"Brands-Nijenhuis","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2019111520473357900_B54","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.31311","article-title":"Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center","volume":"124","author":"Ciurea","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"2019111520473357900_B55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fon-2017-0603","article-title":"CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia","volume":"14","author":"Talati","year":"2018","journal-title":"Future Oncol"},{"issue":"26","key":"2019111520473357900_B56","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111520473357900_B57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.leukres.2013.12.010","article-title":"Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure","volume":"38","author":"Jaglal","year":"2014","journal-title":"Leuk Res"},{"issue":"12","key":"2019111520473357900_B58","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.clml.2017.09.007","article-title":"A phase II study of CLAG regimen combined with imatinib mesylate for relapsed or refractory acute myeloid leukemia","volume":"17","author":"Mirza","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2019111520473357900_B59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2017.22","article-title":"Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2019111520473357900_B60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","article-title":"Relapsed\/refractory acute myeloid leukemia: any progress?","volume":"29","author":"Schlenk","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"2019111520473357900_B61","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2019111520473357900_B62","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111520473357900_B63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2019111520473357900_B64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hon.2393","article-title":"Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed AML","volume":"36","author":"Shimizu","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111520473357900_B65","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjh.14107","article-title":"A prognostic model for survival after salvage treatment with FLAG-Ida +\/- gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia","volume":"174","author":"Bergua","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111520473357900_B66","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111520473357900_B67","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/leu.2013.297","article-title":"Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG","volume":"28","author":"Fiegl","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2019111520473357900_B68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2001.02551.x","article-title":"A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation","volume":"112","author":"Jackson","year":"2001","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111520473357900_B69","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acutre myeloid leukemia and FLT-3 internal tandem duplicatoin mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111520473357900_B70","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3109\/10428194.2015.1135435","article-title":"Midostaurin, bortezomib and MEC in relapsed\/refractory acute myeloid leukemia","volume":"57","author":"Walker","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111520473357900_B71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12185-014-1503-4","article-title":"Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed\/refractory AML","volume":"99","author":"Ramsingh","year":"2014","journal-title":"Int J Hematol"},{"issue":"25","key":"2019111520473357900_B72","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia","volume":"114","author":"Tallman","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111520473357900_B73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2019111520473357900_B74","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"2019111520473357900_B75","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29319","article-title":"Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis","volume":"121","author":"Percival","year":"2015","journal-title":"Cancer"},{"issue":"18","key":"2019111520473357900_B76","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111520473357900_B77","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2019111520473357900_B78","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"2019111520473357900_B79","first-page":"221","article-title":"Relative benefit for intensive versus non-intensive induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) using a composite, age-comorbidity-cytogenetic, model [abstract]","volume":"101","author":"Sorror","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111520473357900_B80","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019 induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2019111520473357900_B81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"2019111520473357900_B82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/asheducation-2018.1.45","article-title":"New drugs for acute myeloid leukemia inspired by genomics and when to use them","volume":"2018","author":"Pollyea","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"33","key":"2019111520473357900_B83","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111520473357900_B84","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22537","article-title":"Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia","volume":"109","author":"Etienne","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"2019111520473357900_B85","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111520473357900_B86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11899-016-0348-8","article-title":"Definition of unfit for standard acute myeloid leukemia therapy","volume":"11","author":"Klepin","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"2019111520473357900_B87","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes","volume":"37","author":"Sherman","year":"2013","journal-title":"Leuk Res"},{"issue":"2","key":"2019111520473357900_B88","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"2019111520473357900_B89","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111520473357900_B90","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111520473357900_B91","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/51\/1256584\/hem01807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/51\/1256584\/hem01807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T15:11:13Z","timestamp":1607267473000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/51\/277625\/Cytotoxic-therapy-in-acute-myeloid-leukemia-not"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.51","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}